We are witnessing an era of increased clinical interest in metastatic castration-resistant prostate cancer, both in terms of treatment and also in terms of imaging options. This surge in interest is attributed to the recent developments in treatments for metastatic prostate cancer that are able to confer a significant survival advantage. We are therefore anticipating an increase in the number of patients that we will need to treat at this disease stage. Imaging is undoubtedly crucial in monitoring disease response to treatment and progression. Bone scintigraphy has evolved recently with new and more sensitive tracers that can accurately diagnose even low volume disease progression. MRI has an established role in the diagnosis of spinal cord compression. The current review aims to focus on the recent developments in bone imaging at this disease stage with a special emphasis on imaging in patients treated with new androgen targeted agents.
Current radiopharmaceuticals. 2017 Aug 16 [Epub ahead of print]
Petros Sountoulides, Linda Metaxa
The Pennine Acute Hospitals, NHS Trust - Urology Manchester. United Kingdom., Barts and The London NHS Trust - Radiology London. United Kingdom.